Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer

Disease Markers

Volumn 2014, Issue , 2014, Pages

  De La Peña, Sol ^a   Sampieri, Clara Luz ^a   Ochoa Lara, Mariana ^a   León Córdoba, Kenneth ^b   Remes Troche, José María ^a  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b Dr Miguel Dorantes Mesa Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MESSENGER RNA; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; TIMP3 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC GASTRITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; ENZYMOLOGY; GASTRITIS; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GASTRITIS; GENE EXPRESSION; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84897010839     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/285906     Document Type: Article

References (48)

1. Brenner H., Rothenbacher D., Arndt V., Epidemiology of stomach cancer. Methods in Molecular Biology 2009 472 467 477 2-s2.0-58149476920 10.1007/978-1-60327-492-0-23
2. de Vries A. C., Meijer G. A., Looman C. W. N., Casparie M. K., Hansen B. E., Van Grieken N. C. T., Kuipers E. J., Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut 2007 56 12 1665 1670 2-s2.0-36749059381 10.1136/gut.2007.127167
3. Meireles S. I., Cristo E. B., Carvalho A. F., Hirata R. Jr., Pelosof A., Gomes L. I., Martins W. K., Begnami M. D., Zitron C., Montagnini A. L., Soares F. A., Neves E. J., Reis L. F. L., Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa. Cancer Research 2004 64 4 1255 1265 2-s2.0-10744233165 10.1158/0008-5472.CAN-03-1850
4. Correa P., Cuello C., Duque E., Gastric cancer in Colombia. III. Natural history of precursor lesions. Journal of the National Cancer Institute 1976 57 5 1027 1035 2-s2.0-0017086391
5. Correa P., The biological model of gastric carcinogenesis. IARC Scientific Publications 2004 157 301 310 2-s2.0-1842851795
6. Genta R. M., Rugge M., Assessing risks for gastric cancer: new tools for pathologists. World Journal of Gastroenterology 2006 12 35 5622 5627 2-s2.0-33750120296
7. Moller H., Heseltine E., Vainio H., Working group report on schistosomes, liver flukes and Helicobacter pylori. International Journal of Cancer 1995 60 5 587 589 2-s2.0-0028899982 10.1002/ijc.2910600502
8. Kim M., Kim H. J., Choi B. Y., Kim J.-H., Song K.-S., Noh S.-M., Kim J. C., Han D. S., Kim S.-Y., Kim Y. S., Identification of potential serum biomarkers for gastric cancer by a novel computational method, multiple normal tissues corrected differential analysis. Clinica Chimica Acta 2012 413 3-4 428 433 2-s2.0-84355161472 10.1016/j.cca.2011.10.026
9. Yoshikawa T., Tsuburaya A., Kobayashi O., Sairenji M., Miyagi Y., Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer 2006 9 2 106 113 2-s2.0-33745115399 10.1007/s10120-006-0362-y
10. Dicken B. J., Bigam D. L., Cass C., Mackey J. R., Joy A. A., Hamilton S. M., Gastric adenocarcinoma: review and considerations for future directions. Annals of Surgery 2005 241 1 27 39 2-s2.0-11044225555 10.1097/01.sla.0000149300. 28588.23
11. Baren J. P., Stewart G. D., Stokes A., Gray K., Pennington C. J., O'Neill R., Deans D. A., Paterson-Brown S., Riddick A. C., Edwards D. R., Fearon K. C., Ross J. A., Skipworth R. J., mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma. British Journal of Cancer 2012 107 143 149
12. Kosaka Y., Mimori K., Fukagawa T., Ishikawa K., Etoh T., Katai H., Sano T., Watanabe M., Sasako M., Mori M., Clinical significance of molecular detection of matrix metalloproteinase-1 in bone marrow and peripheral blood in patients with gastric cancer. Annals of Surgical Oncology 2012 19 supplement 3 S430 S437 2-s2.0-79960150944 10.1245/s10434-011-1905-y
13. Benson A. B., Advanced gastric cancer: an update and future directions. Gastrointestinal Cancer Research 2008 2 47 53
14. Bustin S. A., Benes V., Nolan T., Pfaffl M. W., Quantitative real-time RT-PCR: a perspective. Journal of Molecular Endocrinology 2005 34 3 597 601 2-s2.0-21344458602 10.1677/jme.1.01755
15. Wu C. Y., Wu M. S., Chen Y. J., Chen C.-J., Chen H.-P., Shun C.-T., Chen G.-H., Huang S.-P., Lin J.-T., Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. European Journal of Cancer 2007 43 4 799 808 2-s2.0-33947636758 10.1016/j.ejca.2006.10.022
16. Egeblad M., Werb Z., New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002 2 3 161 174 2-s2.0-0036512208
17. Elnemr A., Yonemura Y., Bandou E., Kinoshita K., Kawamura T., Takahashi S., Tochiori S., Endou Y., Sasaki T., Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 2003 6 1 30 38 2-s2.0-0037267075 10.1007/s101200300004
18. Verma R. P., Hansch C., Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorganic and Medicinal Chemistry 2007 15 6 2223 2268 2-s2.0-33846906016 10.1016/j.bmc.2007.01.011
19. Vincenti M. P., Brinckerhoff C. E., Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Research 2002 4 3 157 164 2-s2.0-0036240838 10.1186/ar401
20. Page-McCaw A., Ewald A. J., Werb Z., Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews Molecular Cell Biology 2007 8 3 221 233 2-s2.0-33847195428 10.1038/nrm2125
21. Baker A. H., Edwards D. R., Murphy G., Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of Cell Science 2002 115 19 3719 3727 2-s2.0-0036800192 10.1242/jcs.00063
22. Nuttall R. K., Sampieri C. L., Pennington C. J., Gill S. E., Schultz G. A., Edwards D. R., Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. The FEBS Letters 2004 563 1-3 129 134 2-s2.0-1842737700 10.1016/S0014-5793(04)00281-9
23. Alakus H., Grass G., Hennecken J. K., Bollschweiler E., Schulte C., Drebber U., Baldus S. E., Metzger R., Hölscher A. H., Mönig S. P., Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histology and Histopathology 2008 23 8 917 923 2-s2.0-46249122672
24. Yoshikawa T., Tsuburaya A., Kobayashi O., Sairenji M., Motohashi H., Yanoma S., Noguchi Y., Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomarker for invasion and its impact on survival. Cancer 2001 91 1739 1744
25. Wu Z. Y., Li J. H., Zhan W. H., He Y. L., Lymp node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World Journal of Gastroenterology 2006 12 19 2941 2944 2-s2.0-33744489345
26. Inoue T., Yashiro M., Nishimura S., Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. International Journal of Molecular Medicine 1999 4 1 73 77 2-s2.0-0033159779
27. Sier C. F. M., Kubben F. J. G. M., Ganesh S., Heerding M. M., Griffioen G., Hanemaaijer R., Van Krieken J. H. J. M., Lamers C. B. H. W., Verspaget H. W., Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. British Journal of Cancer 1996 74 3 413 417 2-s2.0-0030016640
28. Bando E., Yonemura Y., Endou Y., Sasaki T., Taniguchi K., Fujita H., Fushida S., Fujimura T., Nishimura G.-I., Miwa K., Seiki M., Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncology Reports 1998 5 6 1483 1488 2-s2.0-13144275193
29. de la Peña S., Sampieri C., León-Córdoba K., Matrix metalloproteases as molecular markers in gastric cancer. Medicina Clinica 2010 134 3 123 126 2-s2.0-76149089078 10.1016/j.medcli.2009.09.031
30. Bergin P. J., Anders E., Sicheng W., Erik J., Jennie A., Hans L., Pierre M., Qiang P.-H., Marianne Q.-J., Increase production of matrix metalloproteinases in Helicobacter pylori-associated human gastritis. Helicobacter 2004 9 3 201 210 2-s2.0-2642574016 10.1111/j.1083-4389.2004.00232.x
31. Rautelin H. I., Oksanen A. M., Veijola L. I., Sipponen P. I., Tervahartiala T. I., Sorsa T. A., Lauhio A., Enhanced systemic matrix metalloproteinase response in helicobacter pylori gastritis. Annals of Medicine 2009 41 3 208 215 2-s2.0-67650360228 10.1080/07853890802482452
32. Nuttall R. K., Pennington C. J., Taplin J., Wheal A., Yong V. W., Forsyth P. A., Edwards D. R., Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Molecular Cancer Research 2003 1 5 333 345 2-s2.0-0037359601
33. Itoh Y., Ito A., Iwata K., Tanzawa K., Mori Y., Nagase H., Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. Journal of Biological Chemistry 1998 273 38 24360 24367 2-s2.0-0032544524 10.1074/jbc.273.38.24360
34. Sun Q., Weber C. R., Sohail A., Bernardo M. M., Toth M., Zhao H., Turner J. R., Fridman R., MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. Journal of Biological Chemistry 2007 282 30 21998 22010 2-s2.0-34547606200 10.1074/jbc.M701737200
35. Sampieri C. L., de la Peña S., Ochoa-Lara M., Zenteno-Cuevas R., León-Córdoba K., Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World Journal of Gastroenterology 2010 16 12 1500 1505 2-s2.0-77950845621 10.3748/wjg.v16.i12. 1500
36. Murray G. I., Duncan M. E., Arbuckle E., Melvin W. T., Fothergill J. E., Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998 43 6 791 797 2-s2.0-0031769534
37. Allgayer H., Babic R., Grützner K. U., Beyer B. C. M., Tarabichi A., Schildberg F. W., Heiss M. M., Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clinical and Experimental Metastasis 1998 16 1 62 73 2-s2.0-0031938422 10.1023/A:1006564002679
38. Mönig S. P., Baldus S. E., Hennecken J. K., Spiecker D. B., Grass G., Schneider P. M., Thiele J., Dienes H. P., Hölscher A. H., Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001 39 6 597 602 2-s2.0-0035660661 10.1046/j.1365-2559.2001.01306.x
39. Kabashima A., Maehara Y., Kakeji Y., Baba H., Koga T., Sugimachi K., Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clinical Cancer Research 2000 6 9 3581 3584 2-s2.0-0033813250
40. Mrena J., Wiksten J. P., Nordling S., Kokkola A., Ristimäki A., Haglund C., MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. Journal of Clinical Pathology 2006 59 6 618 623 2-s2.0-33745092103 10.1136/jcp.2005.033761
41. He Q., Chen J., Lin H. L., Hu P. J., Chen M. H., Expression of peroxisome proliferator-activated receptor γ E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chinese Medical Journal 2007 120 17 1498 1504 2-s2.0-34848859859
42. Wang L. B., Jiang Z. N., Fan M. Y., Xu C. Y., Chen W. J., Shen J. G., Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer. World Journal of Gastroenterology 2008 14 10 1612 1616 2-s2.0-41549115888 10.3748/wjg.14.1612
43. Mori M., Mimori K., Shiraishi T., Fujie T., Baba K., Kusumoto H., Haraguchi M., Ueo H., Akiyoshi T., Analysis of MT1-MMP and MMP2 expression in human gastric cancers. International Journal of Cancer 1997 74 316 321
44. Gu P., Xing X., Tänzer M., Röcken C., Weichert W., Ivanauskas A., Pross M., Peitz U., Malfertheiner P., Schmid R. M., Ebert M. P. A., Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008 10 6 563 572 2-s2.0-44449102334 10.1593/neo.08208
45. Yokoyama T., Nakamura H., Otani Y., Kubota T., Fujimoto N., Seiki M., Kitajima M., Okada Y., Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3. Clinical and Experimental Metastasis 2004 21 3 223 233 2-s2.0-4344689352 10.1023/B:CLIN.0000037704.72028.72
46. Miyazaki T., Kato H., Nakajima M., Faried A., Takita J., Sohda M., Fukai Y., Yamaguchi S., Masuda N., Manda R., Fukuchi M., Ojima H., Tsukada K., Kuwano H., An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. British Journal of Cancer 2004 91 8 1556 1560 2-s2.0-7944231990 10.1038/sj.bjc.6602185
47. Caenazzo C., Onisto M., Sartor L., Scalerta R., Giraldo A., Nitti D., Garbisa S., Augmented membrane type 1 matrix metalloproteinase (MT1-MMP): MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clinical Cancer Research 1998 4 9 2179 2186 2-s2.0-0031716627
48. Zhang S., Li L., Lin J. Y., Lin H., Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World Journal of Gastroenterology 2003 9 5 899 904 2-s2.0-0038205818